Review Article

Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy

Quan Zhuang, Ruoyu Ma, Yanshuang Yin, Tianhao Lan, Meng Yu, and Yingzi Ming

1Transplantation Center of The 3rd Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
2Research Center of National Health Ministry on Transplantation Medicine, Changsha, Hunan 410013, China
3Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China

Correspondence should be addressed to Yingzi Ming; myz_china@aliyun.com

Received 6 September 2018; Accepted 27 November 2018; Published 13 January 2019

Renal fibrosis, as the fundamental pathological process of chronic kidney disease (CKD), is a pathologic extension of the normal wound healing process characterized by endothelium injury, myofibroblast activation, macrophage migration, inflammatory signaling stimulation, matrix deposition, and remodelling. Yet, the current method of treating renal fibrosis is fairly limited, including angiotensin-converting enzyme inhibition, angiotensin receptor blockade, optimal blood pressure control, and sodium bicarbonate for metabolic acidosis. MSCs are pluripotent adult stem cells that can differentiate into various types of tissue lineages, such as the cartilage (chondrocytes), bone (osteoblasts), fat (adipocytes), and muscle (myocytes). Because of their many advantages like ubiquitous sources, convenient procurement and collection, low immunogenicity, and low adverse effects, with their special identification markers, mesenchymal stem MSC-based therapy is getting more and more attention. Based on the mechanism of renal fibrosis, MSCs mostly participate throughout the renal fibrotic process. According to the latest and overall literature reviews, we aim to elucidate the antifibrotic mechanisms and effects of diverse sources of MSCs on renal fibrosis, assess their efficacy and safety in preliminarily clinical application, answer the controversial questions, and provide novel ideas into the MSC cellular therapy of renal fibrosis.

1. Introduction

Renal fibrosis develops following an accumulation of scar tissue within the parenchyma, and it represents the collaborative ultimate pathway of nearly all the chronic and progressive nephropathies [1]. Affecting more than 10% of the world population with limited treatment options, renal fibrosis remains a major public health conundrum as it is considered the fundamental pathological process of chronic kidney disease (CKD) independent of the underlying etiology [2]. CKD is also one of the strongest risk factors for cardiovascular disease [3, 4]. Although the idea of reversing CKD has been investigated by scientists repeatedly in the past decade, existing treatments that prevent CKD progression and CKD-related complications are quite limited [5] and currently include angiotensin-converting enzyme inhibition, angiotensin receptor blockade, optimal blood pressure control, and sodium bicarbonate for metabolic acidosis [6]. Therefore, the prevention or reversal of renal fibrosis remains ineffective or only slightly successful, and the development of a new strategy for the treatment of this pathological process is extremely urgent.

To date, an increasing number of studies have shown that stem cell treatment is prominently effective in chronic and progressive diseases [7]. Multiple types of stem cells, including mesenchymal stem cells (MSCs) [8], embryonic stem cells (ESCs) [9], and induced pluripotent stem cells (iPSCs) [10], have manifested their qualities as viable and accessible sources for tissue repair and regeneration. Because of the ethical and expense issues, MSCs exhibit advantages compared to ESCs and iPSCs [11]. MSCs are pluripotent adult stem cells that can differentiate into various types of tissue...
lineages, such as the cartilage (chondrocytes), bone (osteoblasts), fat (adipocytes), and muscle (myocytes) [12]. The International Cell Therapy Association has established the minimum standard for human MSC definition [13]: cells must be plastically adherent; exhibit a three-lineage differentiation in osteoblasts, adipocytes, and chondrocytes; and express certain surface patterns of CD105, CD73, and express certain surface patterns of CD105, CD73, and CD90, while lacking CD45, CD34, CD14, CD11b, or CD79a or the expression of CD19, as well as HLA-DR. Moreover, Gli1 may be used as a marker for MSCs according to recent research reports [14]. Since then, MSCs have been proven to be derived from virtually all tissues’ adventitial progenitor cells and pericytes [15]. The most applied tissues include the bone marrow [16], cord cells [17], adipose tissue [18], molar cells [19], amniotic fluid [20], and placenta [21], as well as several solid organs, such as the lung [22], liver [23], and kidney [24]. These MSCs from solid organs are referred to as tissue-resident MSCs [25]. Since Friedenstein and Caplan first defined MSCs according to their multilineage potential [26, 27], MSCs have shown their cellular therapeutic competence in many diseases and pathoepidemiology. It is widely agreed that transplanted MSCs can directly reconstruct impaired organs [28]. MSCs are also capable of producing cytokines, growth factors, and chemokines; moreover, they exert a comprehensive range of functions by expressing extracellular matrix receptors on their cell surface, including antiapoptosis [29], angiogenesis [30], anti-inflammation [31], immune regulation [32], antiscarring [33], and chemically induced homing to damaged tissue, thus supporting the growth and differentiation of diseased cells, which makes them attractive for clinical applications. Fibrosis, as one of the most common and refractory pathological processes, has always drawn substantial attention, and many efforts and trials of MSC cellular therapy have been carried out on antifibrotic diseases [34]. Pondering the origin and therapeutic activities of MSCs, we summarize this network in Figure 1.

In this review, we will discuss the antifibrotic mechanisms and effects of different sources of MSCs on renal fibrosis and evaluate their efficacy and safety in preliminarily clinical application, aiming to provide overall and new insights on MSC cell therapy in renal fibrosis.

2. The Link between Renal Fibrosis and MSCs

Renal fibrosis features a redundant accumulation of extracellular matrix (ECM), which undermines and supplants the functional parenchyma that results in organ failure. Consequently, the imbalance between a superfluous production and lessened reduction of the ECM results in tubulointerstitial fibrosis and glomerulosclerosis. Glomerulosclerosis may be elicited by metabolic, mechanical, or immunological impairments on endothelial cells or podocytes, resulting in an increasing production of ECM by mesangial cells [35]. However, it is commonly agreed that tubulointerstitial fibrosis plays the main role by depositing the matrix protein between the basement membrane and peritubular capillaries.

Four stages may be observed during the pathophysiology of renal fibrosis: (1) cellular activation and injury phase or priming, (2) fibrogenic signaling stimulation phase, (3) fibrogenic phase or execution, and (4) destructive phase or progression [36]. During these phases, several signaling pathways are strongly involved, including nuclear factor-kappaB (NF-κB) [37], transforming growth factor-β1 (TGF-β1)/small mothers against decapentaplegic (Smad) [38], Notch, wingless-type MMTV integration site (Wnt), Hedgehog [39], protein kinase C (PKC)/extracellular regulated protein kinases (ERK), and phosphatidylinositol-3 kinase (PI3K)/Akt [40]. However, TGF-β1/Smad signaling has been considered the central pathway that mediates renal fibrosis and CKD progression among these signaling pathways because TGF-β1/Smad has ubiquitous communications with other signaling pathways in the fibrootic process [41]. The
potential mechanism of renal fibrosis and CKD has been described as follows based on the 4 phases previously noted. Renal epithelial cell injury may be elicited by ischemia, toxins, and proteinuria from many diseases, such as glomerulonephritis, diabetes, or hypertension, and it may lead to fibroblast proliferation [42] and macrophage infiltration [43]. TGF-β1 are consequently released from the damaged and infiltrating cells and act on fibroblast-type cells in the kidney (that is, mesangial cells and fibroblasts) [44], which subsequently induce the epithelial-to-mesenchymal transition (EMT) and cause more ECM deposition [41]. Finally, profibrotic molecules, including collagens, fibronectin, and plasminogen activator inhibitor-1 (PAI-1), may increase and lead to kidney failure [44].

MSCs, as protective fibrotic mediators, play the crucial role in at least the former 3 phases during the renal fibrotic process (Figure 2). Bone marrow-derived MSCs (BM-MSCs) could affect the cellular activation and injury phase through inflammation by reducing the expression of proinflammatory cytokines [45], and it reduces the fibrogenic signaling stimulation phase by signaling pathways, mainly TGF-β1/Smad, as well as NK-κB and ERK. BM-MSCs can inhibit the fibrogenic phase or execution by restraining the EMT [46]. Umbilical cord-derived MSCs (UC-MSCs) can affect the fibrogenic signaling stimulation phase, such as TGF-β1 [47], TLR4/NF-κB [48], ERK [41], and Akt [49] signaling pathways. They can also reduce EMT. Additionally, adipose-derived MSCs (AMSCs) can participate in the cellular activation and injury phase or priming by reducing the release of IL-1β, TNF-α, and IL-6. AMSCs could also inhibit TGF-β1/Smad2/3/7 signaling pathway activation [50]. Therefore, we will discuss the antifibrotic mechanisms and effects of different sources of MSCs on the former 3 fibrotic phases as follows.

3. Mechanisms and Functions of MSCs in Renal Fibrosis Therapy

3.1. Bone Marrow-Derived MSCs. BM-MSCs were the first identified MSCs by Friedenstein et al. in 1966 [26]. Various animal studies have corroborated that extraneous BM-MSCs can improve kidney function in CKD models after infusion. da Silva et al. [51] injected the cultivated syngeneic BM-MSCs and their conditioned medium (CM) to a unilateral ureteral obstruction (UUO) rat through the abdominal vena cava. They found that both MSCs and their CM could decrease the expression levels of collagen 1, α-SMA, TNF-α, caspase 3, and proliferating cell nuclear antigen (PCNA) and ultimately reduce the EMT. However, they did not identify the detailed mechanism. In another study, renal-arterially delivered BM-MSCs also reduce the EMT and renal fibrosis in rat UUO [52]. Wu et al. [53] injected BM-MSC uninephrectomized mice with bovine serum albumin- (BSA-) induced proteinuria to serve as CKD models. They determined that the BM-MSC-treated mice exhibited significantly reduced blood urea nitrogen (BUN) and urine albumin:creatinine ratio (UAACR); moreover, collagen IV and α-SMA message RNAs (mRNAs) were prominently constrained with BM-MSC treatment. In their in vitro experiment, human proximal tubular epithelial cells (PTECs) cultivated in albumin were obtained to mimic the pathological environment of CKD. They showed that EMT, α-SMA, fibronectin, and collagen IV mRNAs were significantly decreased with the presence
of BM-MSCs. They also determined that this process was strongly associated with the phosphorylation of p38 and IκB, two transcription factors in the NF-κB signaling pathway. In a transgenic mouse model that simulates human Alport disease, primary mouse BM-MSCs were injected into transgenic mice that are devoid of the a3-chain of type IV collagen (COL4A3) via the tail vein [54]. Ninichuk et al. [55] determined that no MSCs differentiated into renal cells, and the renal function was not promoted, although MSCs were found to localize to kidneys after injection. However, transplanted MSCs hampered peritubular capillary loss and reduced the diosyncrasy of renal fibrosis, namely, the numbers of α-SMA-positive interstitial myofibroblasts, interstitial volume, and interstitial collagen deposition. Lang and Dai [56] performed a syngeneic BM-MSC transplantation in a streptozotocin- (STZ-) induced diabetic nephropathy rat model. They showed that the expression levels of TGF-β1, PAI-1, and Smad3 were reduced after MSC transduction, which implies that the mechanism likely has a strong connection with suppressing the TGF-β1/Smad3 pathway. And this mechanism is also related to diminishing the expression of PAI-1 protein and abating the deposition of ECM, thus modulating the fibrolinotic system.

Additionally, human BM-MSC transplantation was popularly applied in animal models. Matsu et al. [57] used human BM-MSCs for rat UUO models through the renal artery. On the one hand, they showed that renal obstruction resulted in a substantial increase in the collagen, fibronectin, α-SMA, active STAT3, matrix metalloproteinase-9 (MMP-9), and matrix metalloproteinase-1 (TIMP-1, the tissue inhibitor) expression. On the other hand, exogenously administered human BM-MSCs could alleviate this obstruction-induced kidney fibrosis. And this could be done by inhibiting the activation of STAT3 and the production of STAT3-dependent MMP-9; these findings indicated that the JAK-STAT signaling pathway was involved in the mechanism of MSCs preventing renal fibrosis. Interestingly, MMP-9 has typically been considered an antibacterial index due to its proteolytic activity [58]; however, recent studies indicate that MMPs, particularly MMP-9, are able to degrade the tubular basement membrane and shed away E-cadherin, thereby enhancing the EMT and fibrotic progression in obstruction-induced renal injury [46, 59]. In an Adriamycin-(ADR-) induced nephropathy mouse model, Song and his colleagues [45] showed that the levels of oxidative stress-related molecules (O₂−, H₂O₂, malondialdehyde, and 4-HNE), proinflammatory cytokines (INF-γ, TNF-α, IL-12, IL-4, and COX2), NF-κB, and ERK were significantly decreased with human BM-MSC administration. They also demonstrated these changes in an MSC-renal tubular epithelial cell cocultured system. Furthermore, BM-MSCs may use their secreted vesicles, such as exosomes, which may be loaded with useful nucleic acids and proteins to present to adjacent cells or targeted cells [60]. Using genetic engineering, Wang et al. [61] worked out microRNA- (miR-) let7c overexpressed in human BM-MSCs (defined as miR-let7c-MSCs), which exhibits a therapeutic capability in repairing or reversing established renal fibrosis. They found that miR-let7c-MSC therapy ameliorated kidney injury and markedly inhibited the expression of collagen IV, TGF-β1, MMP-9, and TGF-β type 1 receptor (TGF-βR1) in UUO mice. Furthermore, they utilized bioluminescence imaging and an exosomal inhibitor to visualize how miR-let7c-MSCs transfer miR-let7c by secreted exosome uptake. They also observed that after adding isolated exosomes or indirectly coculturing miR-let7c-MSCs with neighboring rat kidney tubular epithelial cells (NRK52E), the increasing expression of fibrotic genes induced by TGF-β1 in NRK52E was significantly repressed.

In summary, we showed that the vascular administration of BM-MSCs, as the most collected and earliest identified MSCs, or their subsidiary products (exosome or CM) could attenuate the process of fibrosis and temper factors involved in inflammation, apoptosis, and the EMT. These factors typically involved several signaling pathways, mainly TGF-β1/Smad, as well as NK-xB, JAK-STAT, and ERK. We summarized the details of every study above in Table 1 to make a clear display.

### 3.2. Umbilical Cord-Derived MSCs

UC-MSCs are overwhelmingly resourceful, and the collection process is safe and noninvasive [62]. Furthermore, UC-MSCs have presented a lower immunogenicity but a more effectively proliferative manner than BM-MSCs [63, 64]. Moreover, an increasing number of studies have confirmed that UC-MSCs exhibit promising therapeutic characteristics as an uprising resource of stem cells [65]. The umbilical cord is a conduit between the placenta and the developing embryo. During the prenatal phase, the umbilical cord is genetically and physiologically part of the fetus and usually contains two arteries (the umbilical artery) and one vein (the umbilical vein). All these blood vessels are buried in Wharton’s jelly (WJ), which derives from the extraembryonic mesoderm and exerts a protective function [66]. Furthermore, WJ is considered a promising site for collecting MSC [67].

Hence, WJ-derived MSCs (WJ-MSCs) were studied specifically for their functions in treating renal fibrosis. Extraction of WJ-MSCs may be performed in the perivascular, intervascular, and subamniotic areas of the WJ [68]. Rodrigues et al. [47] set up a rat ischemia-reperfusion injury (IRI) model which received human WJ-MSCs intraperitoneally. They found that WJ-MSC-treated rats had better tubular function and promoted glomerular filtration, as well as lower levels of TGF-β1, macrophage infiltration, and the senescence-related protein β-galactosidase. Less macrophage infiltration might be equivalent to less severity of fibrosis [69]. Thus, rats treated with WJ-MSCs have a lower level of renal TGF-β1 and might present less chronic kidney impairment and fibrotic progression. Du et al. [49] labeled and injected human WJ-MSCs into unilateral IRI rats via the tail vein. No observation indicated that labeled cells resided in the injured kidneys. IRI-induced renal fibrosis was abolished by the treatment of these cells with the phenomena of a downregulated collagen content and α-SMA level. Moreover, the Akt signaling pathway was involved in these processes. To further investigate the mechanisms, the same team used the same method to establish an AKI rat model, and they identified...
one of the vital mechanisms: human WJ-MSCs could delay tubular EMT and ameliorate kidney fibrosis. The induction of foreign and native hepatocyte growth factor (HGF) biochemical synthesis at the primary stage of AKI in impaired tubular epithelial cells (TECs) contributes to the recovery of the imbalance between HGF/TGF-β during the renal scar-building process [70]. Moreover, Fan et al. [69] tested the effect of human WJ-MSCs in a rat model with peritoneal dialysis- (PD-) elicited fibrosis. And this model is established via PD solution with methyglyoxal (MGO) [71]. Intraperitoneal administration of human WJ-MSCs into rats considerably alleviated peritoneal fibrosis (decreasing the amount of collagen and α-SMA), the formation of the abdominal cocoon induced by PD/MGO, inflammation, neoangiogenesis, and ultrafiltration failure. They also proved there was a lower level of TGF-β in the WJ-MSC-treated groups, which indicated that the antifibrotic effect of WJ-MSCs might be related to the TGF-β signaling pathway.

Chinese scholars transplanted these icariin- (ICA-, extracted from a kidney-tonifying traditional Chinese medicine Epimedium brevicornum Maxim [72]) treated WJ-MSCs to an adenine-induced chronic renal failure (CRF) rat model via the tail vein. As a result, creatinine and BUN analyses reflected an improvement of renal function. IL-6 and TNF-α in the tissue homogenate and serum were substantially mitigated; however, the anti-inflammatory cytokine was increased. Moreover, the expression levels of bone morphogenetic protein-7 (BMP-7) and basic fibroblast growth factor (bFGF) were significantly higher [73]. In cultured renal cells, BMP-7 reacts against the profibrotic effects of TGF-β and exerts a protective function in both acute and chronic renal injury models [74]. Therefore, ICA-treated WJ-MSCs could reduce the levels of fibrosis in CRF rats. Moreover, ICA-treated WJ-MSCs were better than the application of WJ-MSCs alone as far as the antifibrotic and anti-inflammatory effects are concerned.

In addition, the functions of MVs derived from human WJ-MSCs have received substantial attention recently. Moreover, Zhang and his colleagues [75] injected MVs derived from human WJ-MSCs to the IRI rat, and they found that IRI-initiated fibrosis was abrogated by MVs coincident with renal function amelioration. This process was associated with the suppression of NADPH oxidase (NOX) 2 (the solitary function of reactive oxidative stress (ROS) production). In the same year, they showed that this antifibrotic process also had another potential mechanism. MVs derived from human WJ-MSCs could inhibit the chemokine CX3CL1 expression and reduce the CD68+ macrophage population in the kidney [76]. In the later stage, there were observations of renal function improvement and renal fibrosis amelioration in the MV-treated group. Furthermore, Chen et al. [77] recently added human WJ-MSC-MVs to NRK52E cells, and they found that these MVs could release from G2/M cell cycle arrest via the ERK1/2 signaling pathway. Therefore, these MVs could decrease the expression of collagen deposition-related proteins in NRK52E cells. In a rat donation after cardiac death (DCD) renal transplantation model established by Wu et al. [78], WJ-MSC-derived MVs were intravenously injected into rats immediately after renal transplantation. There were clear improvements in the renal function and survival rate. In the MV group, abolishment of renal fibrosis was identified in the late stage. Furthermore, MVs increased the HGF expression and decreased the α-SMA and TGF-β1 expression in all stages.

There were also some literatures which did introduce whether the UC-MSC came from WJ or not, so we defined these cells as unconfirmed UC-MSCs (uUC-MSCs). Huang et al. [79] injected uUC-MSCs into the UUO rat. The streptavidin-biotin complex (SABC) method was harnessed to track these uUC-MSCs after injection. Consequently, they found that these labeled uUC-MSCs were programmed to engraft an impaired kidney, particularly with the damaged renal interstitium. Also in the UUO model, Liu and his colleagues [80] collected the supernatants (CM) of uUC-MSCs and injected them via the renal artery. They found that this CM could significantly reduce the expression of EMT markers, such as α-SMA, TGF-β1, collagen I, and TNF-α. Moreover, the increasing level of E-cadherin reflected the prominent improvement of interstitial kidney fibrosis. The same team later performed similar experiments and identified a more detailed mechanism. In both UUO-induced in vivo and TGF-β1-induced in vitro experiments, human uUC-MSC CM could facilitate the renal function of

| Researcher          | Fibrogenic signal pathway involved | Delivery method | Animal model                        | Heterogeneity                  |
|---------------------|-----------------------------------|----------------|-------------------------------------|-------------------------------|
| da Silva et al. [51]| Not mentioned                     | Abdominal vena cava | Rat UUO                            | Syngeneic                     |
| Asanuma et al. [52]| Not mentioned                     | Renal artery     | Rat UUO                            | Xenogeneic (from human)       |
| Wu et al. [53]     | P38 and NF-xB                     | i.v.             | Mouse BSA-induced proteinuria (CKD model) | Murine                        |
| Ninichuk et al. [55]| Not mentioned                     | Tail vein        | COLA3-deficient mouse rat STZ-induced diabetic nephropathy | Murine                        |
| Lang and Dai [56]  | TGF-β1/Smad3                       | i.p.             | Rat STZ-induced diabetic nephropathy | Syngeneic                     |
| Matsui et al. [57] | JAK-STAT3                         | Renal artery     | Rat UUO                            | Xenogeneic (from human)       |
| Song et al. [45]   | NF-xB and ERK                      | Tail vein        | ADR-induced nephropathy mouse model | Xenogeneic (from human)       |
| Wang et al. [61]   | TGF-β1                            | i.v.             | Mouse UUO                          | Xenogeneic (from human)       |

i.v.: intravenously; i.p.: intraperitoneally.
UO-induced rats and attenuate ECM accumulation, inflammatory cell infiltration, and their inflammatory cytokine release. Not only that, the uUC-MSC CM could also prominently inhibit the activation of TLR4/NF-κB and the degradation of NF-κBα both in vivo and ex vivo [48]. Moreover, Park et al. established a rat diabetic nephropathy model via an intraperitoneal injection of streptozotocin (STZ). Intravenously administered human uUC-MSCs efficiently decreased renal fibronectin, proteinuria, the downregulation of renal E-cadherin, and α-SMA upregulation in diabetic rats [81]. This study differed from other studies because a delayed treatment of uUC-MSCs was performed (4 weeks after diabetic nephropathy progression).

As previously described, human UC-MSC CM could significantly attenuate renal fibrosis [48, 80]. Some scientists address the true helpers of CM. Similar to BM-MSCs, the “cell-free therapy” strategy, the cell-derived extracellular vesicle (EV) for tissue repair has been broadly used on the basis of the paracrine or endocrine mechanism of MSCs [82]. Zou et al. [83] isolated EVs from the medium of human uUC-MSCs and injected them in rats intravenously after unilateral kidney ischemia. Moreover, the EV treatment could also improve the renal function and mitigate the histological lesion. Furthermore, an increase in the capillary vessel density and a reduction in the indicators of renal fibrosis (α-SMA and EMT) were observed after 2 weeks. EVs, according to the definition, are derived from cell membranes and are heterogeneous groups of vesicles that may be divided into apoptotic bodies (1–5 μm), microvesicles (MVs) (100–1,000 nm), and exosomes (40–100 nm) according to their density, size, and biogenesis [84]. The diameters of the EVs in Zou et al.’s study ranged from 150 to 300 nm, which could be categorized as MVs [76]. Zhou and his colleagues [85] paid more attention to the smaller EVs, the exosomes. They used cisplatin (an anticancer drug) to induce acute kidney injury (AKI) rat models, and human uUC-MSC exosomes were injected into the renal capsule and ultimately into the injured kidneys. They found that there was a significant reduction in the creatinine levels and peripheral BUN, necrosis of proximal kidney tubules, apoptosis, and oxidative stress in rats, as well as the formation of a large amount of tubular protein casts after uUC-MSC exosome treatment. In vitro, the treatment of NRK52E cells with cisplatin alone resulted in a higher apoptosis level, activation of the p38 mitogen-activated protein kinase (p38MAPK) pathway, and increasing oxidative stress, followed by a decrease in cell multiplication and an increase in the expression of caspase 3; however, these processes were somehow alleviated and reversed in the uUC-MSC exosome-treated group. In addition, by activating the ERK 1/2 pathway, it was discovered that uUC-MSC exosomes enhanced cell proliferation. AKI, induced by IRI, contributes to kidney interstitial fibrosis, which is a critical characteristic of CKD and is therefore a high-risk factor in the progression of CKD [86]. Thus, the mechanism and process that occurred in Zhou’s study could be strongly associated with renal fibrosis, and the MAPK p38 and ERK pathways also participated in the formation of renal fibrosis [40].

In addition, in ADR-induced nephropathic athymic rats, the therapeutic effect of transplanting three stromal cell populations (human BM-MSCs, uUC-MSCs, and kidney perivascular cells (kPSCs)) to engraft the damaged kidney via tail vein injection was evaluated. Rota et al. [31] found that all three cell populations protected podocytes from further loss, ameliorated glomerular endothelial cell injury, and weakened the production of PEC bridges and podocytes. This may be interpreted as a mitigation of fibrosis and glomerulosclerosis. By inducing polarization towards the M2 macrophage phenotype and reducing macrophage infiltration, human uUC-MSCs had the most preeminent anti-inflammatory effect compared to other stromal cells. CM from uUC-MSCs shared the same renoprotective properties. Similar to BM-MSCs, we made Table 2 to summarize the key information of every study above.

3.3. Adipose-Derived MSCs. Zuk et al. first successfully isolated MSCs from adipose tissue in 2001 [87]. Adipose tissue has since received considerable attention as an ideal MSC source due to its availability, abundance, and self-filling properties [88]. In vitro, cultured human AMSCs can grow adherently with fibroblast-like morphology [13]. Studies regarding AMSCs are very abundant, including autologous, syngeneic, allogeneic, and xenogeneic AMSC transplantation. The species include human, swine, cat, rat, and mouse.

In syngeneic and autologous AMSC transplantation studies, Song et al. [50] used AMSCs derived from the fat tissue that surrounded the epididymis of Wistar rats and transplanted these AMSCs into the UUO rat model through the tail vein. They observed that AMSCs substantially relieved kidney interstitial fibrosis by reducing the levels of fibroblast-specific protein 1 (FSP-1), α-SMA, EMT, and fibronectin, as well as the inflammatory response (release of IL-1β, TNF-α, and IL-6). They also investigated the following mechanism: AMSCs could inhibit TGF-β1/Smad2/3/7 signaling pathway activation. Burgos-Silva et al. [89] compared the efficacy of AKI and chronic kidney injury (CKI) via AMSC administration. Cultured FVB mouse AMSCs were intraperitoneally administered into FVB mice. As a result, the AMSC-treated animals showed an improvement in kidney function, and the chemokine expression (CXCL-1 and macrophage inflammatory protein 1 alpha (MIP-1α)) and neutrophil infiltrate were both reduced by AMSC administration. For CKI, renal fibrosis was ameliorated by decreased tissue chemokines, interstitial collagen deposition, and cyto-kine expression (INF-γ and eotaxin levels) in the AMSC-treated groups. Similar results were obtained in a mouse IRI model by Donizetti-Oliveira et al. [90], in which after animals showed established fibrosis at 6 weeks, syngeneic AMSC treatment manifested the promotion of renal function, accompanied by lower mRNA expression of collagen I and vimentin and reduced tissue fibrosis. Zou et al. [91] coated mouse AMSCs with antibodies directed against kidney injury molecule-1 (KIM1, a transmembrane protein that is expressed minimally in normal kidneys but upregulated dramatically in damaged kidneys [92]). The coating antibody ab-KIM1 has little effect.
| Researcher          | Cell/substance transferred | Fibrogenic signal pathway involved | Delivery method | Animal model          | Heterogeneity                                           |
|---------------------|----------------------------|-----------------------------------|-----------------|-----------------------|---------------------------------------------------------|
| Rodrigues et al. [47] | WJ-MSC                     | TGF-β1                            | i.p.            | Rat IRI               | Xenogeneic (from human)                                 |
| Du et al. [70]       | WJ-MSC                     | Akt and TGF-β1                    | Tail vein       | Rat IRI               | Xenogeneic (from human)                                 |
| Fan et al. [69]      | WJ-MSC                     | TGF-β                             | i.p.            | Rat peritoneal dialysis - (PD-) elicited fibrosis model | Xenogeneic (from human)                                 |
| Zhang et al. [62]    | WJ-MSC MV                  | NOX 2                             | Caudal vein     | Rat IRI               | Xenogeneic (from human)                                 |
| Wu et al. [78]       | WJ-MSC MV                  | TGF-β1                            | i.v.            | Rat DCD renal transplantation | Xenogeneic (from human)                                 |
| Li et al. [73]       | WJ-MSC                     | TGF-β                             | Tail vein       | Adenine-induced CRF rat model | Xenogeneic (from human)                                 |
| Huang et al. [79]    | uUC-MSC                    | Not mentioned                     | Tail vein       | Rat UUO               | Xenogeneic (from human)                                 |
| Liu et al. [80]      | uUC-MSC CM                 | TGF-β1                            | Renal artery    | Rat UUO               | Xenogeneic (from human)                                 |
| Liu et al. [48]      | uUC-MSC CM                 | TLR4/NF-κB                        | Renal artery    | Rat UUO               | Xenogeneic (from human)                                 |
| Park et al. [81]     | uUC-MSC                    | Not mentioned                     | i.v.            | Rat STZ-induced diabetic nephropathy | Xenogeneic (from human)                                 |
| Zou et al. [76]      | uUC-MSC EV                 | HIF-1α                            | Caudal vein     | Rat IRI               | Xenogeneic (from human)                                 |
| Zhou et al. [85]     | uUC-MSC exosome            | p38MAPK and ERK 1/2               | Renal capsule   | Csplatin-induced AKI rat model | Xenogeneic (from human)                                 |
| Rota et al. [31]     | uUC-MSC                    | Not mentioned                     | Tail vein       | ADR-induced nephropathic athymic rat | Xenogeneic (from human)                                 |
improvement in the capillary density and renal perfusion and attenuation of apoptosis, oxidative damage, and fibrosis (downregulated PAI-1, but no effect on TGF-β expression) in a unilateral renal artery stenosis (RAS) model. In a DCD kidney transplantation rat model, syngeneic AMSCs were injected in two different ways: systemic injection through the penile vein and local injection prior to angiostomy through the renal artery from the donor’s kidney (local injection). Iwai et al. [93] discovered that local injection of AMSCs was prone to attenuation of fibrosis. In line with a literature, BM-MSC therapy may prevent long-term fibrotic changes in the allogeneic transplantation clinical setting [94]. This study suggested that the local injection of AMSCs was a potentially safer route of administration than a high-dosage, intravenous injection. Similar to BM-MSCs and UC-MSCs, there are also studies regarding the “cell-free therapy” of AMSCs; Eirin and his colleagues [95] ultracentrifuged EVs (both small MVs and exosomes) from pig autologous AMSCs and transplanted to the RAS pig model by laying a local irritant coil in the renal artery. Tubulointerstitial fibrosis (trichrome staining) was slightly but significantly decreased by AMSC-derived EVs.

For allogeneic AMSC transplantation studies, in 3 pilot studies, naturally occurring CKD cats enrolled in Quimby et al.’s studies [96] received allogeneic AMSCs every 2 weeks via intravenous injection; the AMSCs were obtained from donor-specific pathogen-free (SPF) cats’ adipose tissue, and the extraction site was the same subcutaneous region on the ventral abdomen adjacent to the umbilicus. The authors reported that only one of the pilot studies showed a significant decrease in serum creatinine concentrations. Another similar cat study performed by the same research team indicated that there were no apparent alterations in BUN, serum creatinine, phosphorus, potassium, GFR by nuclear scintigraphy, UACR, or the packed cell volume in cats injected with allogeneic AMSCs [97].

For xenogeneic AMSC transplantation studies, Katsuno et al. [98] established human AMSCs cultured in low (2%) serum (hLAMSCs) and high (20%) serum (hHAMSCs) and performed a renal subcapsular injection of both hLAMSCs and hHAMSCs into a folic acid-induced AKI rat model. Interstitial fibrosis was less prominent in the hLAMSC-treated group. In contrast, in a cyclosporine-(CsA-) induced nephropathy rat model, after transfection via the tail vein, human AMSCs did not prevent renal injury and interstitial fibrosis and manifested an inclinatory to further renal degradation. The mechanism might be that human AMSCs caused oxidative stress by the effect of CsA [99]. Moreover, exosome-related research is also involved in xenogeneic AMSC transplantation. Zhu and his colleagues [100] injected human AMSCs into a UUO rat model. They found that AMSCs could attenuate AKI and mitigate subsequent renal fibrosis (the levels of α-SMA, collagen I, and TGF-β1/Smad3 phosphorylation). However, these positive effects were demolished by a drug (GW4869) that inhibits the modulation release of exosomes from human AMSCs. Table 3 shows the keynotes of all the studies above.

3.4. Amniotic Fluid and Placenta-Derived MSCs. To prevent diseases such as leukemia [101], lymphoma [102], and aplastic anemia [103], more and more umbilical cord tissues and cells are preserved following the birth of babies. However, other gestational tissues, including the amniotic fluid, placental membranes, and placenta, are constantly disposed as junk after birth. This junk contains abundant highly pluripotent stem cell resources, including MSCs. By conducting amniocentesis in the midterm, amniotic fluid-derived MSCs (AF-MSCs) may be obtained from a small amount of amniotic fluid [104]. The collection of amniotic fluid during routine cesarean deliveries is also a promising method [105]. A method of extracting MSCs from the placenta was introduced by Steigman and Fauza [106], who indicated that by chorionic villus sampling or blunt dissection, the fetal placental specimen could be mechanically separated from the maternal decidua [107]. Currently, almost all studies of AF-MSCs and placenta-derived MSCs (PMSCs) in renal fibrosis are in animal models.

Sedrakyan et al. [108] established a mouse model of Alport syndrome (Col4a5 knockout mice) and transplanted syngeneic AF-MSCs intracardially. The results showed that AF-MSCs prior to the onset of proteinuria delayed interstitial fibrosis and the progression of glomerular sclerosis. An M2 macrophage polarization was also identified in AF-MSC-treated mouse kidneys. Moreover, the fact that AF-MSCs suppress the renin-angiotensin system may contribute to these beneficial effects. Baulier et al. [109] used a porcine model to transplant autologous AF-MSCs directly into the grafted kidney via the renal artery 6 days after isogenic kidney transplantation. The injection of AF-MSCs enhanced tubular and glomerular functions, thereby abrogating fibrosis and increasing the levels of circulating TGF-β, which indicated that autologous AF-MSCs might develop their antifibrotic effect through the TGF-β pathway. Xenogeneic studies are about human AF-MSCs. In an IRI modeled rat, human AF-MSCs were transfused via the abdominal aorta. As a result, human AF-MSCs made significantly less inflammatory cell infiltration and tubular necrosis [110]. In a UUO mouse model, Sun et al. [111] showed that human AF-MSCs could increase the microvascular density, thus ameliorating interstitial fibrosis and protecting kidney functions.

Japanese scholars Tooi et al. [112] showed that human PMSCs confer plasticity on fibroblasts in vitro instead of directly in a fibrosis animal model. They found that PMSC exosomes considerably increased the expression of NANOG (stemness-related genes) mRNA and OCT4 expression in fibroblasts, and these exosomes influence the capability of fibroblasts to differentiate into both osteoblasts and adipocytes, which indicated novel characteristics of PMSCs and the promising potential of applying PMSC exosomes in clinical situations.

3.5. Renal Tissue-Resident MSCs. For one, MSCs could be derived from variant tissues, including the bone marrow, umbilical cord, and adipose tissue, and they have exhibited substantial promise in treating kidney fibrosis as previously described. For another, it has been shown that MSC-like cells
Table 3: Literature summary of AMSC in the antifibrotic process.

| Researcher          | Fibrogenic signal pathway involved | Delivery method | Animal model                          | Heterogenity          | Antifibrotic effect |
|---------------------|-----------------------------------|-----------------|---------------------------------------|-----------------------|---------------------|
| Song et al. [50]    | TGF-β1/Smad2/3/7                  | Tail vein       | Rat UUO                               | Syngeneic             | Yes                 |
| Burgos-Silva et al. [89] | Not mentioned                   | i.p.            | AKI and CKI mouse models             | Syngeneic             | Yes                 |
| Donizetti-Oliveira et al. [90] | TGF-β                      | i.p.            | Mouse IRI                            | Syngeneic             | Yes                 |
| Zou et al. [91]     | PAI-1                             | Carotid artery  | Unilateral RAS mouse model            | Syngeneic             | Yes                 |
| Iwai et al. [93]    | Not mentioned                     | Renal artery    | Rat DCD renal transplantation         | Syngeneic             | Yes                 |
| Eirin et al. [95]   | Not mentioned                     | Renal artery    | RAS pig model                        | Autologous            | Yes                 |
| Quimby et al. [96]  | Not mentioned                     | i.v.            | Cat CKD model                        | Allogeneic            | No                  |
| Katsuno et al. [98] | Not mentioned                     | Renal subcapsule| Folic acid-induced AKI rat model      | Xenogeneic (from human) | Yes                 |
| Chung et al. [99]   | Not mentioned                     | Tail vein       | CsA-induced nephropathy rat model     | Xenogeneic (from human) | No                  |
| Zhu et al. [100]    | TGF-β1/Smad3                      | Tail vein       | Mouse IRI                            | Xenogeneic (from human) | Yes                 |
in vivo reside in the pericyte or perivascular niche, and not only do they later become typical cultured MSCs but they also have strong connections with endothelial cells. Furthermore, they are much more likely to contribute to renal fibrosis by differentiating into myofibroblasts [113]. In the Hedgehog pathway, researchers have determined that Gli1 is a marker expressed specifically in a major population of tissue-resident MSCs, and these Gli1⁺ MSCs form a strong network across organs. Lineage tracing studies have shown that the Gli1 progeny covers injured areas rich in collagen I deposition [14], which indicates that these cells actively synthesize collagen and participate in ECM deposition during transient fibrogenesis.

By establishing UUO and IRI mouse models, Kramann et al. [23] tracked down the fate of genetically labeled Gli1⁺ MSC cells and determined that there was a substantial increase of Gli1⁺ cells throughout the kidney. The later ablation of Gli1⁺ cells after kidney injuries corroborated that there was an imposing amelioration of fibrosis and a stabilization of renal function in mice compared with the sham group. This discovery also applies to other organs, including the liver and lung [24]. Similar research was conducted by Humphreys et al. [114] by tracing the origin of myofibroblasts. After establishing a mouse UUO model, they discovered that kidney epithelial cells did not become myofibroblasts; in contrast, cells deriving from FoxD1, which is a transcription factor expressed in cells, and later becoming kidney mesenchymal stromal cells are the progenitor of myofibroblasts [25]. Studies performed by Leaf et al. [115] demonstrated additional mechanisms of kidney-resident MSCs leading to renal damages. They found that myeloid differentiation primary response 88 (MyD88) and its downstream effector kinase IL-1 receptor-associated kinase 4 (IRAK-4) intrinsically control renal tissue-resident MSC migration and conversion to myofibroblasts. The reason is that IRAK4 and MyD88 regulate inflammation and fibrogenesis, which are the 2 major injury responses in the kidney [116].

3.6. Dental MSCs. Dental stem cells (DSCs) are MSC-like cells that exist in the human body throughout life [117]. There are five types of DSCs: stem cells from human exfoliated deciduous teeth (SHED), periodontal ligament stem cells (PDLCs), dental pulp stem cells (DPSCs), stem cells from apical papilla (SCAP), and dental follicle precursor cells (DFPCs) [118]. Barros et al. [119] explored the homing of cryopreserved DPSCs in an acute renal failure (ARF) rat model. DPSCs demonstrated renotropic and pericyte-like properties, after intravenous or intraperitoneal injection, and contributed to accelerating the regeneration of the renal tubule structure. Furthermore, Hattori et al. [120] verified that in ischemia-reperfusion injury-initiated acute kidney injury, SHED was able to decrease inflammatory cytokines and promote kidney function. Yamaza et al. [121] investigated the immunomodulatory capacity of SHED as a potential treatment in a murine systemic lupus erythematosus (SLE) model. According to the results, the intravenous administration of SHED resulted in a significant reduction in the serum antibody levels, trabecular bone reconstruction, and regulation of Th17 cells. SLE and ARF were both proven to develop CKD (renal fibrosis) [122, 123].

3.7. Peripheral Blood MSCs. Among all tissues and cells, peripheral blood mononuclear cells (PBMCs) seem to be the most convenient to obtain. In research conducted by Pan et al. [124], human PBMCs were collected, purified, and reprogrammed by oocyte-inducing agents into induced mesenchymal stem cells (iMSCs). The iMSCs were subsequently injected into rabbit UUO models. The team indicated that significantly lower BUN and serum creatinine values and higher GFR as well as lower TGF-β1 and almost no fibrosis were identified in the induced group; this study suggested that iMSCs derived from human PBMCs could be a new shortcut in the treatment of chronic kidney diseases.

4. Attempts for MSC-Based Therapy in Clinical Application

As previously described, in most preclinical trials, MSCs exhibit few or no adverse side effects and are safe, while the efficacy remains controversial [96, 97, 109]. However, regarding translation to humans, safety concerns present a strong impediment to the smooth transition from laboratorial MSCs to pragmatic clinical MSC treatment. These safety concerns include the susceptibility to infection due to their immunomodulatory capabilities, potential canceration from the active proliferation of MSCs, embolism of the cells, cellular acute or chronic immunogenicity, and cell culture reagent-induced zoonoses [125]. A meta-analysis of the randomized control trials (RCTs) did not indicate a connection between organ system complications, infection, acute inflammation toxicity, malignancy, or death [126]. In renal fibrosis, scientists have continued attempts with MSC-based therapy in clinical application. Foremost, in phase 1 of the clinical trial conducted by Togel and Westenfelder [127], patients who endured high postoperative AKI risks after cardiac operations safely received allogeneic MSC treatment. In a case of a living-related kidney transplant study, bone marrow tissue of the kidney recipient was collected from the posterior iliac crest to extract autologous BM-MSCs one month before the transplant. Tan et al. [128] found that there was a reduced risk of opportunistic infection, lower possibility of acute rejection, and better predicted kidney function at the 1-year follow-up using autologous MSCs compared with those of anti-IL-2 receptor antibody induction therapy. However, the autologous MSC inoculum was not associated with unfavorable events, and it did not negatively impact kidney transplant survival. Consequently, Reinders and his colleagues [129] carried out a series of clinical trials on the effects and safety of autologous and allogeneic BM-MSCs in renal fibrotic processes. They initially expanded BM-MSCs procured from end-stage renal disease (ESRD) patients and age-matched healthy controls who shared similar phenotypical and functional characteristics. Moreover, they performed a phase I study of autologous BM-MSCs on allograft rejection after renal transplantation. They found that there was tubulitis
resolution in two patients of allograft rejection without tubular atrophy (IF/TA) and interstitial fibrosis. They proved that autologous BM-MSC therapy in transplant with IF/TA and subclinical rejection is practical and safe clinically [130]. They subsequently evaluated whether the combination treatment of autologous BM-MSCs with everolimus, the mTOR inhibitor, which enhances the withdrawal of tacrolimus, could reduce renal fibrosis in renal transplant recipients. They obtained a favorable result from MSCs in regard to renal fibrosis prevention, safety, and the preservation of renal structure and function, which would imply auspicious advancement for patients who are on kidney transplant waiting lists [131]. Out of worry of an antidonor immune response of allogeneic source cell therapy, one year later, they tried to use allogeneic BM-MSCs to confirm their effects and safety also for renal transplant recipients. They concluded that allogeneic MSCs were an effective and safe treatment alternative for renal transplant recipients, particularly when faced with indications where autologous MSC treatment is not technically possible [132]. Recently, a clinical trial from Iran revealed the feasibility and safety of autologous AMSCs in peritoneal dialysis patients (IRCT2015052415841N2). As a result, no unfavorable lesions and no catheter-related complications were found in the participants, and one patient developed an episode of peritonitis and another patient experienced exit site infection, which did not appear to be related to the procedure [133]. Of course, there was also an individual report which revealed potential nephrotoxicity after CKD patients received autologous MSC treatment. Kim et al. reported a case report about autologous AMSC administration for a patient with CKD. Before the MSC administration, the kidney function of the patient was consistently stable for years. Without any other implications of AKI, preexisting renal failure promptly invaded the kidney one week after the treatment of autologous MSC. Hemodialysis was applied 3 months after MSC therapy. Renal biopsy during dialysis demonstrated that with a few cells expressing CD117 and CD34, inflammatory cell infiltration and severe interstitial fibrosis could be observed [134]. Additionally, the researching scale has expanded to more than 500 registered clinical trials (http://clinicaltrials.gov/) in harnessing MSCs for therapeutic purposes at the current stage. We summarized the information of 13 registered MSC clinical trials for renal fibrosis and CKD in Table 4. Generally, the bench-to-bedside transition of MSCs in curing renal fibrosis is tantalizingly promising.

As far as dose and frequency are concerned, there is no exact guideline as to how many cells and how often should a patient be receiving MSC treatment. It is reported that $1 - 2 \times 10^6$/kg of MSCs is most appropriate for the human body [135]. Some authors suggested that a patient should receive two doses of therapy with each time and 7 days apart between two therapies [129, 130]. Others only gave a range on the quantities of MSCs during the treatment; they believe that the frequency should be further elucidated, because various studies have shown that a single infusion may be protective in kidney diseases while two or more infusions have better effects [135].

5. Conclusion, Questions, and Perspectives

MSCs are found in almost all postnatal organs and tissues, including the fat, bone, cartilage, umbilical cord, cord blood, synovium, synovial fluid, muscle, skin, and pulp. MSCs from different sources possess similar morphologies and express identical surface markers. With their ability to differentiate into multiple lineages and migrate toward injured tissue and their propensity to secrete factors identified to be important in tissue recovery, MSCs undoubtedly have great therapeutic potential in renal fibrosis-related diseases. Preclinical and current clinical results seem promising, but moving the concept of MSC-based therapy forward to large-scale clinical application should be assessed critically. There are many ideas on how to manipulate the isolation and purification of MSCs to make them safer and more useful. Like many other cells, manipulation of MSCs in vitro and infusion of MSCs into CKD patients as a form of cell therapy will require many explorations before the real application in clinical practice (Figure 3).

Additionally, some controversial questions should be addressed when actually doing MSC-based therapy.

1. The Injection Way of MSCs. Most injection ways of the studies discussed in this review are systemically intravenous (e.g., peripheral veins) and via the local artery (e.g., renal artery). The former one is more feasible in clinical operation, but the latter one is considered to be more effective because all the MSCs injected seem to localize in the kidney. In actual, there was no difference in therapeutic effects between the systemic and local ways of injection. Not in a kidney disease model, but in a model of permanent middle cerebral artery occlusion, Gutierrez-Fernandez et al. [136] proved that both MSC administration routes (external carotid artery and femoral vein) showed no difference in improving neurological recovery and provided brain protection. Together with the easy operation and low hurt, the systemically intravenous way is more recommended.

2. The Choice of MSC Heterogeneity. Although xenogeneic human MSC transplantation is very common in animal models, the reverse way (animal MSCs to human) is mostly not considered currently because of safety. Therefore, choosing autologous or allogeneic MSC transplantation should be discussed in clinical application. Autologous MSC transplantation should be considered as the best way for MSC-based therapy because of the low immunogenicity and noninfectious feature. However, it takes several weeks to months to manufacture autologous cells due to the expansion period, quality controls, and logistics, and this period of time is too long for patients in need of treatment. Moreover, MSCs derived from patients with renal disease have a lower capacity for kidney regeneration [137]. Allogeneic MSCs offer an “off the shelf” advantage for clinical use and have the potential to be mass-produced rapidly [138]. This would significantly decrease costs and the number of procedures and enable use of cells from young healthy donors that may exhibit higher efficacy than cells from older individuals.
Table 4: Registered clinical trials of MSCs in renal fibrosis and CKD (ClinicalTrial.gov, updated September 2018).

| Registered no. | Status             | Title                                                                 | Population (age: year-old) | Phase | Source of MSCs | Location                                      | Start date   |
|---------------|--------------------|----------------------------------------------------------------------|-----------------------------|-------|----------------|-----------------------------------------------|--------------|
| NCT00659620   | Unknown            | Mesenchymal stem cell transplantation in the treatment of chronic allograft nephropathy | 20 (18-60)                  | 1 and 2 | Bone marrow    | Fuzhou, China                                | May 2008     |
| NCT00733876   | Completed          | Allogeneic multipotent stromal cell treatment for acute kidney injury following cardiac surgery | 15 (>18)                    | 1     | Bone marrow    | Murray, Salt lake city, United States         | August 2008  |
| NCT00734396   | Completed          | Mesenchymal stem cells and subclinical rejection                      | 15 (18-65)                  | 1 and 2 | Bone marrow    | Leiden, Netherlands                          | February 2009|
| NCT01840540   | Completed          | MSC for occlusive disease of the kidney                               | 6 (40-80)                   | 1     | Adipose        | The Nordic network for clinical islet transplantation | April 2013   |
| NCT01967186   | Unknown            | Intraportal or intramuscular site for islets in simultaneous islet and kidney transplantation | 36 (18-65)                  | Not applicable | Bone marrow | Leiden, Netherlands                          | April 2007   |
| NCT02057965   | Recruiting         | Mesenchymal stromal cell therapy in renal recipients                  | 70 (18-75)                  | 2     | Bone marrow    | Leiden, Netherlands                          | March 2014   |
| NCT02166489   | Completed          | Mesenchymal stem cell transplantation in patients with chronic renal failure due to polycystic kidney disease | 6 (18-60)                   | 1     | Bone marrow    | Tehran, Iran                                 | March 2014   |
| NCT02195323   | Completed          | Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) in patients with chronic kidney disease (CKD) | 7 (25-60)                   | 1     | Bone marrow    | Tehran, Iran                                 | April 2014   |
| NCT02266394   | Recruiting         | Hypoxia and inflammatory injury in human renovascular hypertension    | 42 (40-80)                  | 1     | Adipose        | Birmingham, Rochester, Jackson, United States | October 2014  |
| NCT02387151   | Active, not recruiting | Allogeneic mesenchymal stromal cell therapy in renal transplant recipients | 10 (18-75)                  | 1     | Bone marrow    | Leiden, Netherlands                          | March 2015   |
| NCT02565459   | Recruiting         | MSC and kidney transplant tolerance (phase A)                        | 22 (18-75)                  | 1     | Bone marrow    | Bergamo, Italy                               | September 2015|
| NCT02966717   | Active, not recruiting | Rituximab combined with MSCs in the treatment of PNS (3-4 stages of CKD)  | 116 (18-65)                 | 2     | Not mentioned  | Guangzhou, China                             | August 2016  |
| NCT03321942   | Recruiting         | Treatment of chronic renal failure with adipose tissue-derived mesenchymal stem cells | 100 (18-75)                 | Not applicable | Adipose        | Xuzhou, China                                | January 2017 |
Last but not the least, many popular and novel techniques can be used for investigating the mechanism and clinical efficacy of MSC-based therapy in renal fibrosis.

(1) RNA Array and Proteomics. Because of the safety of cell therapy, delivery of MSC-derived EVs could be an attractive cell-free therapy for renal disease. Just like a pickup truck, EVs, as the delivery of cell-cell communication, can take many useful substances, mainly RNAs and proteins, to affect target cells [61]. Characterization of the transcriptome of human BM-MSCs and their relative-derived EVs using real-time quantitative polymerase chain reaction (RT-qPCR) arrays revealed that EVs contain a wide range of mRNAs [139]. Moreover, the study of miRNAs (thought to be the product of “junk DNA” before) is a rapidly expanding field, and in recent years, several miRNA families have been implicated in kidney fibrosis. According to RNA array, there are numerous miRNAs found in kidney disease, and the main families are miRNA-let-7, miRNA-21, and miRNA-29 [140]. Haraszti et al. [141] identified 3,532 proteins and 1,961 lipid species in MSC-derived EVs by high-resolution lipidomic and proteomic analyses. All the array techniques could provide abundant information for the mechanism of MSC-based therapy.

(2) New Biomaterials. Bae et al. [142] made a three-dimensional bioprinting of an artificial trachea carrying in vitro cultured rabbit BM-MSCs and respiratory epithelial cells. In addition, in order to solve the problems of the cell washout and immune attack during MSC administration, Hwang et al. [143] created an “intravascular paracrine factor (PF) factory” by harnessing stem cells on a stent using a nanofiber (NF) stent sleeve, thus providing a sheltered milieu for cells to continuously produce PFs on-stent. NF stent sleeves were created by covering stents with electrospun poly-lactic-co-glycolic acid nanofibers and were then uniformly coated with MSCs. Moreover, Huang et al. [144] found that exosomes derived from DPSCs and BM-MSCs could bind to the ECM, and they were deduced along with cell-derived ECM-incorporated biomaterials. And these exosomes can be used to recreate a complete extracellular environment that can enable safe and reliable differentiation of stem cells.

In summary, MSC-based therapy in renal fibrosis has become more and more acceptable because of their many advantages like ubiquitous sources, convenient procurement and collection, low immunogenicity, and low adverse effects. We believe it will keep the flame of cellular therapy burning and sparkling.

Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions
Quan Zhuang and Ruoyu Ma contributed equally to this work.

Acknowledgments
This study was supported by grants from the National Natural Science Foundation of China (81700658 and 81771722), the Natural Science Foundation of Hunan Province (2016JJ4105), the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (JY201629), and the University Student Innovation Program of Central South University (ZY20180983 and ZY20180988).

References
[1] B. D. Humphreys, “Mechanisms of renal fibrosis,” Annual Review of Physiology, vol. 80, no. 1, pp. 309–326, 2018.
[2] S. Djudjaj and P. Boor, “Cellular and molecular mechanisms of kidney fibrosis,” Molecular Aspects of Medicine, 2018.
[3] S. Skampardoni, D. Poulilakos, M. Malik, D. Green, and P. A. Kalra, “The potential of electrocardiography for cardiac risk prediction in chronic and end-stage kidney disease,” Nephrology Dialysis Transplantation, no. article gfy255, 2018.
[4] S. Lalan, S. Jiang, D. K. Ng et al., “Cardiometabolic risk factors, metabolic syndrome, and chronic kidney disease
progression in children,” *The Journal of Pediatrics*, vol. 202, pp. 163–170, 2018.

[5] National Kidney Foundation, “KDOQI clinical practice guideline for diabetes and CKD: 2012 update,” *American Journal of Kidney Diseases*, vol. 60, no. 5, pp. 850–886, 2012.

[6] A. J. Collins, R. N. Foley, B. Chavers et al., “2013 USRDS Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States,” *American Journal of Kidney Diseases*, vol. 63, pp. e1–e478, 2014.

[7] T. Li, Z. Ai, and W. Ji, “Primate stem cells: bridge the translation from basic research to clinic application,” *Science China Life Sciences*, vol. 61, pp. 1–10, 2018.

[8] A. I. Caplan and D. Correa, “The MSC: an injury drugstore,” *Cell Stem Cell*, vol. 9, no. 1, pp. 11–15, 2011.

[9] J. T. Taiani, H. R. Buie, G. M. Campbell et al., “Embryonic stem cell therapy improves bone quality in a model of impaired fracture healing in the mouse; tracked temporally using in vivo micro-CT,” *Bone*, vol. 64, pp. 263–272, 2014.

[10] M. Csobonyeiova, S. Polak, and L. Danisovic, “Generation of pancreatic β-cells from iPSCs and their potential for type 1 diabetes mellitus replacement therapy and modelling,” *Experimental and Clinical Endocrinology & Diabetes*, 2018.

[11] J. R. Perez, D. Kouroupis, D. J. Li, T. M. Best, L. Kaplan, and D. Correa, “Tissue engineering and cell-based therapies for fractures and bone defects,” *Front Bioeng Biotechnol*, vol. 6, p. 105, 2018.

[12] J. A. Ankrum, J. F. Ong, and J. M. Karp, “Mesenchymal stem cells: immune evasive, not immune privileged,” *Nature Biotechnology*, vol. 32, no. 3, pp. 252–260, 2014.

[13] E. M. Horwitz, K. Le Blanc, M. Dominici et al., “Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement,” *Cytotherapy*, vol. 7, no. 5, pp. 393–5, 2005.

[14] C. Kuppe and R. Kramann, “Role of mesenchymal stem cells in kidney injury and fibrosis,” *Current Opinion in Nephrology and Hypertension*, vol. 25, no. 4, pp. 372–377, 2016.

[15] A. W. James, J. N. Zara, M. Corselli et al., “An abundant perivascular source of stem cells for bone tissue engineering,” *Stem Cells Translational Medicine*, vol. 1, no. 9, pp. 673–684, 2012.

[16] D. Park, J. A. Spencer, B. I. Koh et al., “Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration,” *Cell Stem Cell*, vol. 10, no. 3, pp. 259–272, 2012.

[17] S. Kandoi, L. Praveen Kumar, B. Patra et al., “Evaluation of platelet lysate as a substitute for FBS in explant and enzymatic isolation methods of human umbilical cord MSCs,” *Scientific Reports*, vol. 8, no. 1, article 12439, 2018.

[18] N. Bertheuil, B. Chaput, C. Menard et al., “Adipose mesenchymal stromal cells: definition, immunomodulatory properties, mechanical isolation and interest for plastic surgery,” *Annales de Chirurgie Plastique Esthétique*, 2018.

[19] S. Jang, Y. H. Kang, I. Ullah et al., “Cholinergic nerve differentiation of mesenchymal stem cells derived from long-term cryopreserved human dental pulp in vitro and analysis of their motor nerve regeneration potential in vivo,” *International Journal of Molecular Sciences*, vol. 19, no. 8, 2018.

[20] T. Laowanitwattana, S. Aungsuchawan, S. Narakornsak et al., “Osteoblastic differentiation potential of human amniotic fluid-derived mesenchymal stem cells in different culture conditions,” *Acta Histochemica*, vol. 120, no. 8, pp. 701–712, 2018.

[21] A. Bier, P. Berenstein, N. Kronfeld et al., “Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy,” *Biomaterials*, vol. 174, pp. 67–78, 2018.

[22] D. Jun, C. Garat, J. West et al., “The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation,” *Stem Cells*, vol. 29, no. 4, pp. 725–735, 2011.

[23] R. Kramann, R. K. Schneider, D. P. DiRocco et al., “Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis,” *Cell Stem Cell*, vol. 16, no. 1, pp. 51–66, 2015.

[24] R. Kramann, J. Wongboonsin, M. Chang-Panesso, F. G. Machado, and B. D. Humphreys, “Gli1 pericyte loss induces capillary rarefaction and proximal tubular injury,” *Journal of the American Society of Nephrology*, vol. 28, no. 3, pp. 776–784, 2017.

[25] D. R. Lemos and J. S. Duffield, “Tissue-resident mesenchymal stromal cells: implications for tissue-specific antiinfective therapies,” *Science Translational Medicine*, vol. 10, no. 426, article eaan5174, 2018.

[26] A. J. Friedenstein, S. Piatetzky II, and K. V. Petракова, “Osteogenesis in transplants of bone marrow cells,” *Journal of Embryology and Experimental Morphology*, vol. 16, no. 3, pp. 381–390, 1966.

[27] A. I. Caplan, “Mesenchymal stem cells,” *Journal of Orthopaedic Research*, vol. 9, no. 5, pp. 641–650, 1991.

[28] S. Hossaini, L. Taghiyar, F. Safari, and M. Baghaban Esfami, “Regenerative medicine applications of mesenchymal stem cells,” in *Cell Biology and Translational Medicine, Volume 2*, K. Turkse, Ed., vol. 1089 of Advances in Experimental Medicine and Biology, Springer, Cham, 2018.

[29] R. Guiho, K. Biteau, G. Grisendi et al., “In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models,” *Cytotherapy*, vol. 20, no. 8, pp. 1037–1045, 2018.

[30] C. Zhang, Y. Du, H. Yuan et al., “HAMS C/HBMS C coculture system ameliorates osteogenesis and angiogenesis against glucolipotoxicity,” *Biochimie*, vol. 152, pp. 121–133, 2018.

[31] C. Rota, M. Morigi, D. Cerullo et al., “Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease,” *Stem Cell Research & Therapy*, vol. 9, no. 1, p. 220, 2018.

[32] F. Hua, Y. Chen, Z. Yang, X. Teng, H. Huang, and Z. Shen, “Protective action of bone marrow mesenchymal stem cells in immune tolerance of allogeneic heart transplantation by regulating CD45RB+ dendritic cells,” *Clinical Transplantation*, vol. 32, no. 4, article e13231, 2018.

[33] R. M. Harman, M. K. He, S. Zhang, and G. R. van de Walle, “Plasminogen activator inhibitor-1 and tenascin-C secreted by equine mesenchymal stromal cells stimulate dermal fibroblast migration in vitro and contribute to wound healing in vivo,” *Cytotherapy*, vol. 20, no. 8, pp. 1061–1076, 2018.

[34] E. El Agha, R. Kramann, R. K. Schneider et al., “Mesenchymal stem cells in fibrotic disease,” *Cell Stem Cell*, vol. 21, no. 2, pp. 166–177, 2017.
L. S. Gewin, A. A. Manresa, D. J. Leeming, M. A. Karsdal, and P. Boor, “The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?,” Fibrogenesis & Tissue Repair, vol. 7, no. 1, p. 4, 2014.

W. Wang, X. Wang, X. S. Zhang, and C. Z. Liang, "Cryptotanshinone attenuates oxidative stress and inflammation through the regulation of Nrf-2 and NF-κB in mice with unilateral ureteral obstruction," Basic & Clinical Pharmacology & Toxicology, vol. 123, no. 6, pp. 714–720, 2018.

A. Loboda, M. Sobczak, A. Jozkowicz, and J. Dulak, “TGF-β1/Smad and miR-21 in renal fibrosis and inflammation,” Mediators Inflamm., vol. 2016, article 8319283, 12 pages, 2016.

M. Edeling, G. Ragi, S. Huang, H. Pavenstadt, and K. Susztak, “Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog,” Nature Reviews. Nephrology, vol. 12, no. 7, pp. 426–439, 2016.

M. Liu, X. Ning, R. Li et al., “Signalling pathways involved in hypoxia-induced renal fibrosis,” Journal of Cellular and Molecular Medicine, vol. 21, no. 7, pp. 1248–1259, 2017.

L. Chen, T. Yang, D. W. Lu et al., “Central role of dysregulation of TGF-β1/Smad in CKD progression and potential targets of its treatment,” Biomedicine & Pharmacotherapy, vol. 101, pp. 670–681, 2018.

L. S. Gewin, “Renal fibrosis: primacy of the proximal tubule,” Matrix Biology, vol. 68-69, pp. 248–262, 2018.

X. Peng, J. Zhang, Z. Xiao, Y. Dong, and J. Du, “CX3CL1–CX3CR1 interaction increases the population of Ly6C CX3CR1hi macrophages contributing to unilateral ureteral obstruction–induced fibrosis,” The Journal of Immunology, vol. 195, no. 6, pp. 2797–2805, 2015.

X. M. Meng, D. J. Nikolic-Paterson, and H. Y. Lan, “TGF-β: the master regulator of fibrosis,” Nature Reviews Nephrology, vol. 12, no. 6, pp. 325–338, 2016.

I. H. Song, K. J. Jung, T. J. Lee et al., “Mesenchymal stem cells attenuate adriamycin-induced nephropathy by diminishing oxidative stress and inflammation via downregulation of the NF-κB,” Nephrology, vol. 23, no. 5, pp. 483–492, 2018.

X. Wang, Y. Zhou, R. Tan et al., “Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy,” American Journal of Physiology Renal Physiology, vol. 299, no. 5, pp. F973–F982, 2010.

C. E. Rodrigues, J. M. Cachpa, A. C. de Bragança et al., “Human umbilical cord-derived mesenchymal stromal cells protect against premature renal senescence resulting from oxidative stress in rats with acute kidney injury,” Stem Cell Research & Therapy, vol. 8, no. 1, p. 19, 2017.

B. Liu, F. Ding, D. Hu et al., “Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro,” Stem Cell Research & Therapy, vol. 9, no. 1, p. 7, 2018.

T. Du, J. Cheng, L. Zhong et al., “The alleviation of acute and chronic kidney injury by human Wharton’s jelly-derived mesenchymal stromal cells triggered by ischemia-reperfusion injury via an endocrine mechanism,” Cytotherapy, vol. 14, no. 10, pp. 1215–1227, 2012.

Y. Song, C. Peng, S. Lv et al., “Adipose-derived stem cells ameliorate renal interstitial fibrosis through inhibition of EMT and inflammatory response via TGF-β signaling pathway,” International Immunopharmacology, vol. 44, pp. 115–122, 2017.

A. F. da Silva, K. Silva, L. A. Reis, V. P. Teixeira, and N. Schor, “Bone marrow-derived mesenchymal stem cells and their conditioned medium attenuate fibrosis in an irreversible model of unilateral ureteral obstruction,” Cell Transplantation, vol. 24, no. 12, pp. 2657–2666, 2015.

H. Asanuma, B. A. Vanderbrink, M. T. Campbell et al., “Arterially delivered mesenchymal stem cells prevent obstruction-induced renal fibrosis,” The Journal of Surgical Research, vol. 168, no. 1, pp. e51–e59, 2011.

H. J. Wu, W. H. Yiu, R. X. Li et al., “Mesenchymal stem cells modulate albumin-induced renal tubular inflammation and fibrosis,” PLoS One, vol. 9, no. 3, article e90883, 2014.

L. H. Noel, “Renal pathology and ultrastructural findings in Alport’s syndrome,” Renal Failure, vol. 22, no. 6, pp. 751–758, 2000.

V. Niniuchuk, O. Gross, S. Segerer et al., “Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3−deficient mice,” Kidney International, vol. 70, no. 1, pp. 121–129, 2006.

H. Lang and C. Dai, “Effects of bone marrow mesenchymal stem cells on plasminogen activator inhibitor-1 and renal fibrosis in rats with diabetic nephropathy,” Archives of Medical Research, vol. 47, no. 2, pp. 71–77, 2016.

F. Matsui, S. A. Babitz, A. Rhee, K. L. Hile, H. Zhang, and K. K. Meldrum, “Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production,” American Journal of Physiology. Renal Physiology, vol. 312, no. 1, pp. F25–F32, 2017.

R. J. Tan and Y. Liu, “Matrix metalloproteinases in kidney homeostasis and diseases,” American Journal of Physiology. Renal Physiology, vol. 302, no. 11, pp. F1351–F1361, 2012.

G. Zheng, J. G. Lyons, T. K. Tan et al., “Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-β1 in renal tubular epithelial cells,” The American Journal of Pathology, vol. 175, no. 2, pp. 580–591, 2009.

S. D. Olson, K. Pollock, A. Kambal et al., “Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington’s disease,” Molecular Neurobiology, vol. 45, no. 1, pp. 87–98, 2012.

B. Wang, K. Yao, B. M. Huuskes et al., “Mesenchymal stem cells deliver exogenous microRNA-let7c via exosomes to attenuate renal fibrosis,” Molecular Therapy, vol. 24, no. 7, pp. 1290–1301, 2016.

B. Zhang, M. Wang, A. Gong et al., “HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing,” Stem Cells, vol. 33, no. 7, pp. 2158–2168, 2015.

C. Mennan, S. Brown, H. McCarthy et al., “Mesenchymal stromal cells derived from whole human umbilical cord exhibit similar properties to those derived from Wharton’s
[64] R. N. Garcia, J. M. Santos, M. Filipe et al., “What makes umbilical cord tissue-derived mesenchymal stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells?,” Stem Cells International, vol. 2015, Article ID 583984, 14 pages, 2015.

[65] J. Zhao, G. Yu, M. Cai et al., “Bibliometric analysis of global scientific activity on umbilical cord mesenchymal stem cells: a swiftly expanding and shifting focus,” Stem Cell Research & Therapy, vol. 9, no. 1, p. 32, 2018.

[66] J. Spurway, P. Logan, and S. Pak, “The development, structure and blood flow within the umbilical cord with particular reference to the venous system,” Australasian Journal of Ultrasound in Medicine, vol. 15, no. 3, pp. 97–102, 2012.

[67] I. Kalaszcynska and K. Ferdyn, “Whatton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance,” BioMed Research International, vol. 2015, Article ID 430847, 11 pages, 2015.

[68] M. S. Joerger-Messerli, C. Marx, B. Oppliger, M. Mueller, D. V. Surbek, and A. Schoeberlein, “Mesenchymal stem cells from Wharton’s jelly and amniotic fluid,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 31, pp. 30–44, 2016.

[69] Y. P. Fan, C. C. Hsia, K. W. Tseng et al., “The therapeutic potential of human umbilical mesenchymal stem cells from Wharton’s jelly in the treatment of rat peritoneal dialysis-induced fibrosis,” Stem Cells Translational Medicine, vol. 5, no. 2, pp. 235–247, 2016.

[70] T. Du, X. Zou, J. Cheng et al., “Human Wharton’s jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells,” Stem Cell Research & Therapy, vol. 4, no. 3, p. 59, 2013.

[71] I. Hirahara, E. Kusano, S. Yanagiba et al., “Peritoneal injury by methylglyoxal in peritoneal dialysis,” Peritoneal Dialysis International, vol. 26, no. 3, pp. 380–392, 2006.

[72] Z. B. Sun, J. W. Wang, H. Xiao et al., “Icariin may benefit the mesenchymal stem cells of patients with steroid-associated osteonecrosis by ABCB1-promoter demethylation: a preliminary study,” Osteoporosis International, vol. 26, no. 1, pp. 187–197, 2015.

[73] W. Li, L. Wang, X. Chu, H. Cui, and Y. Bian, “Icariin combined with human umbilical cord mesenchymal stem cells significantly improve the impaired kidney function in chronic renal failure,” Molecular and Cellular Biochemistry, vol. 428, no. 1-2, pp. 203–212, 2017.

[74] D. F. Higgins, L. M. Ewart, E. Masterson et al., “BMP7-induced-Pten inhibits Akt and prevents renal fibrosis,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1863, no. 12, pp. 3095–3104, 2017.

[75] G. Zhang, X. Zou, S. Miao et al., “The anti-oxidative role of micro-vesicles derived from human Wharton-jelly mesenchymal stromal cells through NOX2/gp91(phox) suppression in alleviating renal ischemia-reperfusion injury in rats,” PLoS One, vol. 9, no. 3, article e92129, 2014.

[76] X. Zou, G. Zhang, Z. Cheng et al., “Microvesicles derived from human Wharton’s jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1,” Stem Cell Research & Therapy, vol. 5, no. 2, p. 40, 2014.

[77] W. Chen, Y. Yan, C. Song, Y. Ding, and T. Du, “Microvesicles derived from human Wharton’s jelly mesenchymal stem cells ameliorate ischemia-reperfusion-induced renal fibrosis by releasing from G2/M cell cycle arrest,” The Biochemical Journal, vol. 474, no. 24, pp. 4207–4218, 2017.

[81] J. H. Park, J. Park, S. H. Hwang, H. Han, and H. Ha, “Delayed treatment with human umbilical cord blood-derived stem cells attenuates diabetic renal injury,” Transplantation Proceedings, vol. 44, no. 4, pp. 1123–1126, 2012.

[84] S. Nani, A. E. Ryan, M. D. Griffin, and T. Ritter, “Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications,” Molecular Therapy, vol. 23, no. 5, pp. 812–823, 2015.

[87] P. A. Zuk, M. Zhu, H. Mizuno et al., “Mesenchymal stem cells of patients with steroid-associated renal transplantation, Cell Transplantation, vol. 7, no. 2, pp. 211–228, 2001.

[89] Z. Wang and D. Sun, “Adipose-derived mesenchymal stem cells: a new tool for the treatment of renal fibrosis,” Stem Cells and Development, vol. 27, no. 20, pp. 1406–1411, 2018.

[91] X. Zou, K. Jiang, A. S. Puranik et al., “Targeting murine mesenchymal stem cells to kidney injury molecule-1 improves their therapeutic efficacy in chronic ischemic kidney injury,”
T. Ichimura, J. V. Bonventre, V. Bailly et al., “Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury,” *The Journal of Biological Chemistry*, vol. 273, no. 7, pp. 4135–4142, 1998.

S. Iwai, I. Sakonju, S. Okano et al., “Impact of ex vivo administration of mesenchymal stem cells on the function of kidney grafts from cardiac death donors in rat,” *Transplantation Proceedings*, vol. 46, no. 5, pp. 1578–1584, 2014.

S. Oyagi, M. Hirose, M. Kojima et al., “Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats,” *Journal of Hepatology*, vol. 44, no. 4, pp. 742–748, 2006.

A. Eurin, X. Y. Zhu, A. S. Puranik et al., “Mesenchymal stem cell–derived extracellular vesicles attenuate kidney inflammation,” *International Journal of Kidney*, vol. 92, no. 1, pp. 114–124, 2017.

J. M. Quimby, T. L. Webb, L. M. Habenicht, and S. W. Dow, “Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies,” *Stem Cell Research & Therapy*, vol. 4, no. 2, p. 48, 2013.

J. M. Quimby, T. L. Webb, E. Randall, A. Marolf, A. Valdes-Martinez, and S. W. Dow, “Assessment of intravenously adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats,” *Journal of Feline Medicine and Surgery*, vol. 18, no. 2, pp. 165–171, 2016.

T. Katsuno, T. Ozaki, Y. Saka et al., “Low serum cultured adipose tissue-derived stromal cells ameliorate acute kidney injury in rats,” *Cell Transplantation*, vol. 22, no. 2, pp. 287–297, 2013.

B. H. Chung, S. W. Lim, K. C. Doh, S. G. Piao, S. B. Heo, and C. W. Yang, “Human adipose tissue derived mesenchymal stem cells aggravate chronic cyclosporin nephrotoxicity by the induction of oxidative stress,” *PLoS One*, vol. 8, no. 3, article e59693, 2013.

F. Zhu, O. L. S. Chong Lee Shin, G. Pei et al., “Adipose-derived mesenchymal stem cells employed exosomes to attenuate AKI-CKD transition through tubular epithelial cell dependent Sox9 activation,” *Oncotarget*, vol. 8, no. 41, pp. 70707–70726, 2017.

L. Silla, F. Dulley, R. Saboya et al., “Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia,” *European Journal of Haematology*, vol. 98, no. 2, pp. 177–183, 2017.

A. Paviglianiti, K. Tozatto Maio, V. Rocha et al., “Outcomes of advanced Hodgkin lymphoma after umbilical cord blood transplantation: a Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party study,” *Biology of Blood and Marrow Transplantation*, vol. 24, no. 11, pp. 2265–2270, 2018.

X. Zhang, Z. Li, W. Geng, B. Song, and C. Wan, “Effects and predictive factors of immunosuppressive therapy combined with umbilical cord blood infusion in patients with severe aplastic anemia,” *Yonsei Medical Journal*, vol. 59, no. 5, pp. 643–651, 2018.

D. Moschidou, S. Mukherjee, M. P. Blundell et al., “Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic acid acquire pluripotent characteristics,” *Stem Cells and Development*, vol. 22, no. 3, pp. 444–458, 2013.

A. Kaviani, T. E. Perry, A. Dzakovic, R. W. Jennings, M. M. Ziegler, and D. O. Fauza, “The amniotic fluid as a source of cells for fetal tissue engineering,” *Journal of Pediatric Surgery*, vol. 36, no. 11, pp. 1662–1665, 2001.

S. A. Steigman and D. O. Fauza, “Isolation of mesenchymal stem cells from amniotic fluid and placenta,” *Current Protocols in Stem Cell Biology*, vol. 35, pp. 1E.2.1–1E.2.14, 2007.

Y. Fukushima, H. Nakajima, D. Sugiyama, I. Hirose, T. Kitamura, and K. Tsuji, “Human placenta-derived cells have mesenchymal stem/progenitor cell potential,” *Stem Cells*, vol. 22, no. 5, pp. 649–658, 2004.

S. Sedrakyan, S. Da Sacco, A. Milanesi et al., “Injection of amniotic fluid stem cells delays progression of renal fibrosis,” *Journal of the American Society of Nephrology*, vol. 23, no. 4, pp. 661–673, 2012.

E. Baulier, F. Favreau, A. Le Corf et al., “Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal function in a preclinical porcine model of kidney transplantation,” *Stem Cells Translational Medicine*, vol. 3, no. 7, pp. 809–820, 2014.

M. G. M. C. M. da Cunha, S. Zia, F. Oliveira Arcolino et al., “Amniotic fluid derived stem cells with a renal progenitor phenotype inhibit interstitial fibrosis in renal ischemia and reperfusion injury in rats,” *PLoS One*, vol. 10, no. 8, article e0136145, 2015.

D. Sun, L. Bu, C. Liu et al., “Therapeutic effects of human amniotic fluid-derived stem cells on renal interstitial fibrosis in a murine model of unilateral ureteral obstruction,” *PLoS One*, vol. 8, no. 5, article e65042, 2013.

M. Tooi, M. Komaki, C. Morioka et al., “Placenta mesenchymal stem cell derived exosomes confer plasticity on fibroblasts,” *Journal of Cellular Biochemistry*, vol. 117, no. 7, pp. 1658–1670, 2016.

I. A. Leaf and J. S. Duffield, “What can target kidney fibrosis?”, *Nephrology Dialysis Transplantation*, vol. 32, Supplement 1, pp. i89–i97, 2017.

B. D. Humphreys, S. L. Lin, A. Kobayashi et al., “Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis,” *The American Journal of Pathology*, vol. 176, no. 1, pp. 85–97, 2010.

I. A. Leaf, S. Nakagawa, B. G. Johnson et al., “Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury,” *The Journal of Clinical Investigation*, vol. 127, no. 1, pp. 321–334, 2017.

S. Nakagawa, “Identification of biomarkers for tubular injury and interstitial fibrosis in chronic kidney disease,” *Yakugaku Zasshi*, vol. 137, no. 11, pp. 1355–1360, 2017.

T. Gong, B. C. Heng, E. C. Lo, and C. Zhang, “Current advance and future prospects of tissue engineering approach to dentin/pulp regenerative therapy,” *Stem Cells International*, vol. 2016, Article ID 9204574, 13 pages, 2016.

J. Botelho, M. A. Cavacas, V. Machado, and J. J. Mendes, “Dental stem cells: recent progresses in tissue engineering and regenerative medicine,” *Annals of Medicine*, vol. 49, no. 8, pp. 644–651, 2017.

M. A. Barros, J. F. Martins, D. A. Maria et al., “Immature dental pulp stem cells showed renotropic and pericyte-like...
properties in acute renal failure in rats,” *Cell Medicine*, vol. 7, no. 3, pp. 95–108, 2015.

[120] Y. Hattori, H. Kim, N. Tsuboi et al., “Therapeutic potential of stem cells from human exfoliated deciduous teeth in models of acute kidney injury,” *PLoS One*, vol. 10, no. 10, article e0140121, 2015.

[121] T. Yamaza, A. Kentaro, C. Chen et al., “Unusual teeth,” *Stem Cell Research & Therapy*, vol. 1, no. 1, p. 5, 2010.

[122] M. Scherling, V. Guillotin, M. E. Truchetet et al., “Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets,” *Autoimmunity Reviews*, vol. 17, no. 6, pp. 625–635, 2018.

[123] Y. Sato and M. Yanagita, “Immune cells and inflammation in AKI to CKD progression,” *American Journal of Physiology-Renal Physiology*, vol. 315, no. 6, pp. F1501–F1512, 2018.

[124] X. H. Pan, J. Zhou, X. Yao et al., “Transplantation of induced mesenchymal stem cells for treating chronic renal insufficiency,” *PLoS One*, vol. 12, no. 4, article e0176273, 2017.

[125] D. J. Prockop, M. Brenner, W. E. Fibbe et al., “Defining the risks of mesenchymal stromal cell therapy,” *Cytotherapy*, vol. 12, no. 5, pp. 576–578, 2010.

[126] M. M. Lalu, L. McIntyre, C. Pugliese et al., “Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials,” *PLoS One*, vol. 7, no. 10, article e47559, 2012.

[127] F. E. Togel and C. Westenfelder, “Mesenchymal stem cells: a new therapeutic tool for AKI,” *Nature Reviews Nephrology*, vol. 6, no. 3, pp. 179–183, 2010.

[128] J. Tan, W. Wu, X. Xu et al., “Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial,” *JAMA*, vol. 307, no. 11, pp. 1169–1177, 2012.

[129] M. E. Reinders, M. Roemeling-van Rhijn, M. Khairoun et al., “Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy,” *Cytotherapy*, vol. 15, no. 6, pp. 663–672, 2013.

[130] M. E. Reinders, J. W. de Fijter, H. Roelofs et al., “Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study,” *Stem Cells Translational Medicine*, vol. 2, no. 2, pp. 107–111, 2013.

[131] M. E. Reinders, J. R. Bank, G. J. Dreyer et al., “Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients,” *Journal of Translational Medicine*, vol. 12, no. 1, p. 331, 2014.

[132] M. E. Reinders, G. J. Dreyer, J. R. Bank et al., “Safety of allogeic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the Neptune study,” *Journal of Translational Medicine*, vol. 13, no. 1, p. 344, 2015.

[133] S. Alatab, S. Shekarchian, I. Najafi et al., “Systemic infusion of autologous adipose tissue-derived mesenchymal stem cells in peritoneal dialysis patients: feasibility and safety,” *Cell Journal*, vol. 20, no. 4, pp. 483–495, 2019.

[134] J. S. Kim, J. H. Lee, O. Kwon et al., “Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy,” *Kidney Research and Clinical Practice*, vol. 36, no. 2, pp. 200–204, 2017.

[135] C. Chen and J. Hou, “Mesenchymal stem cell-based therapy in kidney transplantation,” *Stem Cell Research & Therapy*, vol. 7, no. 1, p. 16, 2016.

[136] M. Gutierrez-Fernandez, B. Rodriguez-Frutos, J. Alvarez-Grech et al., “Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats,” *Neuroscience*, vol. 175, pp. 394–405, 2011.

[137] P. E. Westerweel, I. E. Hoefer, P. J. Blankestein et al., “End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells,” *American Journal of Physiology. Renal Physiology*, vol. 292, no. 4, pp. F1132–F1140, 2007.

[138] N. Trainor, A. Pietak, and T. Smith, “Rethinking clinical delivery of adult stem cell therapies,” *Nature Biotechnology*, vol. 32, no. 8, pp. 729–735, 2014.

[139] A. A. Narges, L. O. Lerman, and A. Eirin, “Mesenchymal stem cell derived extracellular vesicles for renal repair,” *Current Gene Therapy*, vol. 17, no. 1, pp. 29–42, 2017.

[140] K. Yao and S. D. Ricardo, “Mesenchymal stem cells as novel micro-ribonucleic acid delivery vehicles in kidney disease,” *Nephrology*, vol. 21, no. 5, pp. 363–371, 2016.

[141] R. A. Haraszti, M. C. Didiot, E. Sapp et al., “High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources,” *Journal of Extracellular Vesicles*, vol. 5, no. 1, article 32570, 2016.

[142] S. W. Bae, K. W. Lee, J. H. Park et al., “3D bioprinted artificial trachea with epithelial cells and chondrogenic–differentiated bone marrow-derived mesenchymal stem cells,” *International Journal of Molecular Sciences*, vol. 19, no. 6, 2018.

[143] C. W. Hwang, P. V. Johnston, G. Gerstenblith et al., “Stem cell impregnated nanofiber stent sleeve for on-stent production and intravascular delivery of paracrine factors,” *Biomaterials*, vol. 52, pp. 318–326, 2015.

[144] C. C. Huang, R. Narayanan, S. Alapati, and S. Ravindran, “Exosomes as biomimetic tools for stem cell differentiation: applications in dental pulp tissue regeneration,” *Biomaterials*, vol. 111, pp. 103–115, 2016.